[go: up one dir, main page]

WO2001076600A3 - Inhibition de la production de cytokines - Google Patents

Inhibition de la production de cytokines Download PDF

Info

Publication number
WO2001076600A3
WO2001076600A3 PCT/US2001/011474 US0111474W WO0176600A3 WO 2001076600 A3 WO2001076600 A3 WO 2001076600A3 US 0111474 W US0111474 W US 0111474W WO 0176600 A3 WO0176600 A3 WO 0176600A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibition
cytokine generation
generation
cytokine
desloratadine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/011474
Other languages
English (en)
Other versions
WO2001076600A2 (fr
Inventor
Robert P Schleimer
John Schroeder
William Kreutner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Priority to CA002405413A priority Critical patent/CA2405413A1/fr
Priority to MXPA02009821A priority patent/MXPA02009821A/es
Priority to EP01928407A priority patent/EP1267870A2/fr
Priority to JP2001574117A priority patent/JP2003530351A/ja
Priority to AU2001255268A priority patent/AU2001255268A1/en
Publication of WO2001076600A2 publication Critical patent/WO2001076600A2/fr
Publication of WO2001076600A3 publication Critical patent/WO2001076600A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention concerne l'utilisation de desloratadine pour préparer un médicament destiné à inhiber la production de cytokines pro-inflammatoires telles que IL-4 et IL-13 chez un patient humain nécessitant une telle inhibition.
PCT/US2001/011474 2000-04-07 2001-04-05 Inhibition de la production de cytokines Ceased WO2001076600A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002405413A CA2405413A1 (fr) 2000-04-07 2001-04-05 Inhibition de la production de cytokines
MXPA02009821A MXPA02009821A (es) 2000-04-07 2001-04-05 Inhibicion de la generacion de citocina.
EP01928407A EP1267870A2 (fr) 2000-04-07 2001-04-05 Inhibition de la production de cytokines
JP2001574117A JP2003530351A (ja) 2000-04-07 2001-04-05 サイトカイン生成の阻害
AU2001255268A AU2001255268A1 (en) 2000-04-07 2001-04-05 Inhibition of cytokine generation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19601600P 2000-04-07 2000-04-07
US60/196,016 2000-04-07

Publications (2)

Publication Number Publication Date
WO2001076600A2 WO2001076600A2 (fr) 2001-10-18
WO2001076600A3 true WO2001076600A3 (fr) 2002-06-27

Family

ID=22723784

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/011474 Ceased WO2001076600A2 (fr) 2000-04-07 2001-04-05 Inhibition de la production de cytokines

Country Status (6)

Country Link
EP (1) EP1267870A2 (fr)
JP (1) JP2003530351A (fr)
AU (1) AU2001255268A1 (fr)
CA (1) CA2405413A1 (fr)
MX (1) MXPA02009821A (fr)
WO (1) WO2001076600A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050192261A1 (en) * 2003-09-15 2005-09-01 Jost-Price Edward R. Methods and reagents for the treatment of immunoinflammatory disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595997A (en) * 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595997A (en) * 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HAYASHI S. ET AL: "Anti-inflammatory actions of new antihistamines.", CLINICAL AND EXPERIMENTAL ALLERGY, (1999) 29/12 (1593-1596)., XP001025988 *
LIPOZENCIC J.: "The EAACI 1997 annual meeting - A message from he meeting Rhodes, June 1-5, 1997.", ACTA DERMATOVENEROLOGICA CROATICA, (1997) 5/2 (69-80)., XP001018736 *
LIPPERT, U. ET AL: "Pharmacological modulation of IL-6 and IL-8 secretion by the H1-antagonist decarboethoxy-loratadine and dexamethasone by human mast and basophilic cell lines", EXP. DERMATOL. (1995), 4(4, PT. 2), 272-6, XP001001161 *
SEGURA T. ET AL: "Allergic rhinitis: Basic pathophysiology and therapeutic strategies.", CANADIAN JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, (1999) 4/7 (318-330)., XP000998728 *

Also Published As

Publication number Publication date
CA2405413A1 (fr) 2001-10-18
WO2001076600A2 (fr) 2001-10-18
AU2001255268A1 (en) 2001-10-23
JP2003530351A (ja) 2003-10-14
MXPA02009821A (es) 2003-03-27
EP1267870A2 (fr) 2003-01-02

Similar Documents

Publication Publication Date Title
AU2001286940A1 (en) Drug delivering prostheses and methods of use
AU2001298042A1 (en) Optimized pulsatile-flow ventricular-assist device and total artificial heart
AU2002340999A1 (en) Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use
AU2001251616A1 (en) Remote patient care
HUP0401461A3 (en) Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use
AU2002213357A1 (en) Variant igg3 rituxan r and therapeutic use thereof
AU2001261762A1 (en) Tilting and reclining wheelchair
AU2001290229A1 (en) Pyridazinones and triazinones and medicinal use thereof
AU2001272840A1 (en) Adjustable chair and method of use
AU2001294834A1 (en) Recombinant bcg vaccines for the prevention and treatment of cancer
AU2002252976A1 (en) Hydrazones and their therapeutic use
AU6900201A (en) Breath-controlled therapeutic inhalation device
AU2002359618A1 (en) Medicinal compositions and therapeutic methods
WO2001076600A3 (fr) Inhibition de la production de cytokines
IL165612A0 (en) Novel arylimidazole derivatives preparation and therapeutic uses thereof
AU2003300772A1 (en) Preventive and therapeutic aids vaccines
AU2000275035A1 (en) Therapeutic and prophylactic drugs of myopia
AU2001284084A1 (en) Polyfluoroalkyltriazole derivatives, preparation and therapeutic use thereof
AU2001255168A1 (en) Compositions and methods for the treatment of immune related diseases
AU6106801A (en) Trans-clitoral administration of therapy
AU2908501A (en) Combination therapy for the treatment of inflammatory and respiratory diseases
IL150237A0 (en) Benzophenone glycopyranosides, preparation and therapeutic use
AU2001294929A1 (en) Human drug metabolizing enzymes
AU2001272552A1 (en) Oxygen-enriched agent and the use thereof for therapeutic purposes
PL111588U1 (en) Medical chair an ambulance

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CZ DE DK DM DZ EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX MZ NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CZ DE DK DM DZ EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX MZ NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2405413

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 574117

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/009821

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2001928407

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001928407

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001928407

Country of ref document: EP